Details

Autor(en) / Beteiligte

• Albarrán, Víctor
• San Román, María
• Pozas, Javier
• Chamorro, Jesús
• Rosero, Diana Isabel
• Guerrero, Patricia
• Calvo, Juan Carlos
• González, Carlos
• García de Quevedo, Coral
• Pérez de Aguado, Patricia
• Moreno, Jaime
• Cortés, Alfonso
• Soria, Ainara

Titel

Adoptive T cell therapy for solid tumors: current landscape and future challenges

Ist Teil von

• Frontiers in immunology, 2024-03, Vol.15, p.1352805-1352805

Ort / Verlag

Switzerland: Frontiers Media S.A

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Adoptive cell therapy (ACT) comprises different strategies to enhance the activity of T lymphocytes and other effector cells that orchestrate the antitumor immune response, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) gene-modified T cells, and therapy with tumor-infiltrating lymphocytes (TILs). The outstanding results of CAR-T cells in some hematologic malignancies have launched the investigation of ACT in patients with refractory solid malignancies. However, certain characteristics of solid tumors, such as their antigenic heterogeneity and immunosuppressive microenvironment, hamper the efficacy of antigen-targeted treatments. Other ACT modalities, such as TIL therapy, have emerged as promising new strategies. TIL therapy has shown safety and promising activity in certain immunogenic cancers, mainly advanced melanoma, with an exciting rationale for its combination with immune checkpoint inhibitors. However, the implementation of TIL therapy in clinical practice is hindered by several biological, logistic, and economic challenges. In this review, we aim to summarize the current knowledge, available clinical results, and potential areas of future research regarding the use of T cell therapy in patients with solid tumors.